https://pipelinereview.com/Syros-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-SY-1365-Its-First-in-Class-Selective-CDK7-Inhibitor-in-Patients-with-Advanced-Solid-Tumors/